• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lipidor

Less than 1K followers
All
Press releases
ShowingAll content types

Regulatory press release5/25/2025, 3:25 PM

Lipidor applies for bankruptcy

Lipidor
Regulatory press release5/24/2025, 10:40 AM

Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis

Lipidor
Press release5/19/2025, 6:30 AM

Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2

Lipidor

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/9/2025, 12:25 PM

Lipidor AB (publ) publishes annual report for 2024

Lipidor
Press release3/17/2025, 7:30 AM

Lipidor announces all patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release2/28/2025, 7:30 AM

Lipidor AB (publ) publishes year-end report for 2024

Lipidor
Press release1/21/2025, 7:00 AM

Lipidor announces half of patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release12/3/2024, 7:00 AM

Lipidor presents Nomination Committee

Lipidor
Press release11/20/2024, 7:00 AM

Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"

Lipidor
Press release9/24/2024, 4:30 PM

Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

Lipidor
Regulatory press release8/28/2024, 6:30 AM

Lipidor AB (publ) publishes interim report for Q2 2024

Lipidor
Press release8/20/2024, 11:50 AM

Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan

Lipidor
Regulatory press release7/1/2024, 6:15 AM

Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue

Lipidor
Regulatory press release6/25/2024, 7:57 PM

Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants

Lipidor
Regulatory press release6/13/2024, 6:46 PM

Lipidor announces final outcome in the rights issue

Lipidor
Regulatory press release6/12/2024, 6:58 PM

Lipidor announces preliminary outcome in the rights issue

Lipidor
Regulatory press release6/7/2024, 6:30 AM

Last day of trading in unit rights in Lipidor's rights issue

Lipidor
Regulatory press release6/5/2024, 8:00 AM

Bulletin from the Annual General Meeting of Lipidor AB (publ)

Lipidor
Regulatory press release5/29/2024, 6:30 AM

Lipidor invites to digital presentations with Q&A

Lipidor
Regulatory press release5/29/2024, 6:00 AM

Today the subscription period in Lipidor's rights issue begins

Lipidor